536565
TRIMURTHI
Start SIP
Invest Now
Start SIP in TRIMURTHI
Performance
- Low
- ₹60
- High
- ₹64
- 52 Week Low
- ₹25
- 52 Week High
- ₹70
- Open Price₹60
- Previous Close₹63
- Volume9,045
- 50 DMA₹58.16
- 100 DMA₹53.93
- 200 DMA₹45.29
Investment Returns
- Over 1 Month + 9.41%
- Over 3 Month + 13.57%
- Over 6 Month + 49.24%
- Over 1 Year + 147.26%
Smart Investing Starts Here Start SIP with Novelix Pharmaceuticals for Steady Growth!
Novelix Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.
- P/E Ratio
- 113.8
- PEG Ratio
- 0
- Market Cap Cr
- 110
- P/B Ratio
- 3.8
- Average True Range
- 3.59
- EPS
- -
- Dividend Yield
- 0
- MACD Signal
- 0.8
- RSI
- 60.41
- MFI
- 70.71
Novelix Pharmaceuticals Financials
Novelix Pharmaceuticals Technicals
EMA & SMA
Current Price
₹62.68
-0.3
(-0.48%)
- Bearish Moving Average 0
- Bullish Moving Average 16
- 20 Day
- ₹60.08
- 50 Day
- ₹58.16
- 100 Day
- ₹53.93
- 200 Day
- ₹45.29
Resistance and Support
61.93
- R3 67.25
- R2 65.13
- R1 64.05
- S1 60.85
- S2 58.73
- S3 57.65
Novelix Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends
| Date | Purpose | Remarks |
|---|---|---|
| 2026-02-12 | Quarterly Results | |
| 2025-11-13 | Quarterly Results | |
| 2025-08-14 | Quarterly Results & A.G.M. | |
| 2025-06-24 | Others | Inter alia, to consider and approve 1. The conversion of Warrants into Equity Shares of the Company. |
| 2025-05-27 | Audited Results |
Novelix Pharmaceuticals F&O
About Novelix Pharmaceuticals
- NSE Symbol
- TRIMURTHI
- BSE Symbol
- 536565
- ISIN
- INE314I01036
Similar Stocks to Novelix Pharmaceuticals
Novelix Pharmaceuticals FAQs
Novelix Pharmaceuticals share price is ₹62 As on 11 February, 2026 | 17:31
The Market Cap of Novelix Pharmaceuticals is ₹110.4 Cr As on 11 February, 2026 | 17:31
The P/E ratio of Novelix Pharmaceuticals is 113.8 As on 11 February, 2026 | 17:31
The PB ratio of Novelix Pharmaceuticals is 3.8 As on 11 February, 2026 | 17:31
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.